We concluded that the activation status of signaling components of downstream pathways of EGFR such as AKT, ERK, STAT3, and NF-κB contributed to the sensitivity and could serve as potential biomarkers of gefitinib in HNSCC patients [30]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.